Join the Hydrocodone group to help and get support from people like you.
Hydrocodone News
Mom's Opioid Use in Pregnancy Raises Child's Asthma, Eczema Risk
THURSDAY, Jan. 18, 2024 – Fetal exposure to opioids may change a baby's immune system, triggering a rise in risks for eczema and asthma through early childhood, new research shows. Children born to...
Recent Reduction Seen in Opioid Prescribing by Surgeons
THURSDAY, Jan. 18, 2024 – Opioid prescribing by surgeons decreased between 2013 and 2017, according to a study published online Jan. 16 in the Journal of the American College of Surgeons. Apostolos ...
You're Far Less Likely to Get an Opioid Now After Surgery
MONDAY, Dec. 11, 2023 – In response to the ongoing crisis of opioid misuse, U.S. doctors had already cut the amount of opioids they gave patients after surgery by 2022 to just a third of the amount...
Teen Surgery-Linked Opioid Prescription Rates Stable From 2015 to 2020
TUESDAY, Oct. 10, 2023 – For U.S. adolescents, there was a decrease in opioid prescription rates from 2015 to 2020 for nonsurgical indications, but opioid prescription rates associated with surgery...
FDA Medwatch Alert: Drug Safety Communication: All Opioid Pain Medicines - FDA Updates Prescribing Information to Provide Additional Guidance for Safe Use
ISSUE: The FDA is requiring several updates to the prescribing information for both immediate-release (IR) and extended release/long acting (ER/LA) opioid pain medicines. This includes stating for a...
FDA Approves Symproic (naldemedine) for the Treatment of Opioid-Induced Constipation
OSAKA, Japan and FLORHAM PARK, N.J. and STAMFORD, Conn., March 23, 2017 /PRNewswire/ – Shionogi Inc. and Purdue Pharma L.P. announced today that the U.S. Food and Drug Administration (FDA) approved...
Teva Receives FDA Approval for Vantrela ER (hydrocodone bitartrate) Extended-Release Tablets Formulated with Proprietary Abuse Deterrence Technology
JERUSALEM--(BUSINESS WIRE)--Jan. 18, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the U.S. Food and Drug Administration (FDA) approved Vantrela ER (hydrocodone...
FDA Medwatch Alert: Opioid Pain or Cough Medicines Combined With Benzodiazepines: Drug Safety Communication - FDA Requiring New Boxed Warnings About Serious Risks and Death
ISSUE: FDA review has found that the growing combined use of opioid medicines with benzodiazepines or other drugs that depress the central nervous system (CNS) has resulted in serious side effects,...
FDA Medwatch Alert: Opioid Pain Medicines: Drug Safety Communication - New Safety Warnings Added to Prescription Opioid Medications
ISSUE: FDA is warning about several safety issues with the entire class of opioid pain medicines. See the FDA Drug Safety Communication for a complete listing. These safety risks are potentially h...
FDA Approves Narcan (naloxone) Nasal Spray to Treat Opioid Overdose
November 18, 2015 – Today the U.S. Food and Drug Administration approved Narcan nasal spray, the first FDA-approved nasal spray version of naloxone hydrochloride, a life-saving medication that can...
Zogenix Receives FDA Approval for New Abuse-Deterrent Formulation of Zohydro ER
SAN DIEGO, Jan. 30, 2015 – Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced...
FDA Approves Hysingla ER - Extended-Release Hydrocodone with Abuse-Deterrent Properties
November 20, 2014 – The U.S. Food and Drug Administration today approved Hysingla ER (hydrocodone bitartrate), an extended-release (ER) opioid analgesic to treat pain severe enough to require daily,...
FDA Approves Zohydro ER, an Extended-Release, Single-Entity Hydrocodone Product
October 25, 2013 – The U.S. Food and Drug Administration today approved Zohydro ER (hydrocodone bitartrate extended-release capsules) for the management of pain severe enough to require daily,...